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Aim To present our 10-year clinical experience with brucel-
losis patients at the University Clinic for Infectious Diseases 
and Febrile Conditions in Skopje, Republic of Macedonia.
Methods A total of 550 patients with brucellosis treated 
between 1998 and 2007 were retrospectively assessed for 
their demographic, epidemiological, and clinical charac-
teristics and outcomes.
Results Of the 550 patients, 395 (72%) were male. The me-
dian age was 34.5 years (range, 1-82). Direct contact with 
infected animals was recorded in 333 (61%) patients and 
positive family history in 310 (56%). The most frequent-
ly seen symptoms were arthralgia (438, 80%), fever (419, 
76%), and sweating (394, 72%). The most common signs 
were fever and hepatomegaly, which were verified in 357 
(65%) and 273 (50%) patients, respectively. Focal brucello-
sis was found in 362 patients (66%) and osteoarticular in 
299 (54%). Therapeutic failures were registered in 37 (6.7%) 
patients. Of the 453 (82%) patients who completed a fol-
low-up period of at least 6 months, relapses occurred in 
60 (13%).
Conclusion Due to non-specific clinical manifestation 
and laboratory parameters, brucellosis should be consid-
ered one of the differential diagnoses of any patient suffer-
ing from obscure involvement of various organs in a bru-
cellosis-endemic region. High percentage of relapses and 
therapeutic failures in spite of the use of currently recom-
mended therapeutic regimens indicates the seriousness of 
this zoonosis and the need to control it.
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Brucellosis is a zoonosis caused by intracellular bacteria of 
the genus Brucella (1). The disease is widespread in many 
countries of the Mediterranean basin, and together with 
hydatidosis, trichinellosis, and leishmaniasis, it is consid-
ered to be a typical Mediterranean zoonosis (2). Human 
brucellosis is a multisystem disease whose patients pres-
ent with nonspecific symptoms (3) and a high risk of com-
plications, a protracted clinical course, and relapses (4).
The main clinical characteristics of human brucellosis have 
been well known for a long time. Marston had been the 
first to give an accurate description of brucellosis as a dis-
ease entity even before the etiological agent was detected 
(5). The monographs published by Hughes in 1897 (6) and 
Spink in 1956 (7) contain perhaps the most detailed and 
still accurate data on this topic. Today, there is a lot of in-
formation about the characteristics of human brucellosis 
available from various parts of the world, and the descrip-
tion of its characteristics varies widely.
For almost 30 years, brucellosis has been a dominant zoo-
nosis in the Republic of Macedonia, causing a high mor-
bidity and huge economic losses. However, the main rea-
sons for persistence of the disease are not only husbandry 
practices and traditional food and living habits (2), but also 
an inadequate strategy of brucellosis control (8). The aim 
of our study was to present more detailed insights into the 
predominant demographic, epidemiological, clinical, and 
laboratory features of brucellosis patients, and their out-
comes, during a 10-year period in the endemic region of 
the Republic of Macedonia.
MethoDS
This retrospective study included 550 patients who were 
diagnosed with brucellosis and treated at the University 
Clinic for Infectious Diseases and Febrile Conditions in Sko-
pje between January 1998 and December 2007. The diag-
nosis was based on clinical findings compatible with bru-
cellosis (arthralgia, fever, sweating, malaise, hepatomegaly, 
splenomegaly, signs of focal disease), supported by detec-
tion of specific antibodies at significant titers and/or dem-
onstration of at least a 4-fold rise in antibody titer in serum 
samples obtained 3-4 weeks apart. Antibody titers were 
determined by standard tube agglutination (STA), Brucel-
la Coombs test (9,10), or the Brucellacapt assay (11). The 
corresponding titers considered positive were ≥1/160, 
≥1/320, and >1/320, respectively. During the study pe-
riod, bacteriological isolation was not a routine practice 
in the Republic of Macedonia.
Demographic and epidemiological data, clinical symptoms 
and signs, laboratory characteristics and outcome of the 
patients were analyzed. If a focal form of the disease was 
suspected after clinical examination, further investigations 
were performed, such as x-rays, electrocardiography, ultra-
sound investigations, lumbar puncture, radionuclide bone 
scan, computerized tomography, magnetic resonance im-
aging, and electromyography.
The patients were treated with various combinations of 
two or three of the following drugs: (a) oral doxycycline at 
100-200 mg/d in patients ≥8 years of age; (b) oral rifampin 
at 600-900 mg/d in adults or 15-20 mg/kg/d in children; 
(c) oral trimethoprim (TMP)-sulfamethoxazole (SMZ) com-
bination therapy at TMP doses of 160-320 mg/d and SMZ 
doses of 800-1600 mg/d in adults, or TMP doses of 10-12 
mg/kg/d and SMZ doses of 50-60 mg/kg/d in children; (d) 
oral ciprofloxacin at 1000 mg/d in adults; (e) intramuscu-
lar gentamicin at 240 mg/d in adults or 5 mg/kg/d in chil-
dren, and (f ) intravenous ceftriaxone at 4 g/d in adults or 
80 mg/kg/d in children. Doxycycline, TMP-SMZ, rifampin, 
and ciprofloxacin were administered for 45-60 days; gen-
tamicin, for the first 7-14 days. Ceftriaxone was part of the 
antimicrobial therapy in patients suffering from neurobru-
cellosis and was administered for 14-30 days. In patients 
with spondylitis, neurobrucellosis, endocarditis and those 
with therapeutic failures, antimicrobial treatment was pro-
longed for at least 3 months.
Osteoarticular involvement was considered to be pres-
ent if there were any inflammatory signs in peripheral os-
teoarticular locations (swelling, pain, functional disability, 
heat, and redness of the joints), or inflammatory pain in 
deep osteoarticular locations concurrently with patho-
logic findings on x-rays, radionuclide bone scans, com-
puterized tomography, or magnetic resonance imaging 
(12). Orchitis and epididymitis were diagnosed by the 
presence of swelling and tenderness of the testis and ep-
ididymis, respectively. Hepatic involvement was defined 
as more than a 2-fold increase in alanine aminotransfer-
ase levels above the reference values (13). Neurobrucel-
losis was defined as presence of neurological dysfunc-
tion, not otherwise explainable, in combination with 
pathologic laboratory findings in the cerebrospinal fluid, 
ie, >10 cells/mL or protein concentrations >0.45 g/L and 
detection of anti-Brucella antibodies (14,15). Endocarditis 
was confirmed by auscultation of a cardiac murmur and 
detection of valvular vegetations using trans-thoracic 
echocardiography (15). Respiratory complications were 
defined by the protocol described by Pappas et al (16). 
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Hematological parameters were described according to 
the criteria published by Troy et al (17). However, hema-
tological involvement was considered to be present only 
in patients with manifestations due to hematological dis-
crasia.
Therapeutic failure was defined as persistence of symp-
toms and signs attributable to the disease after two months 
of antibiotic treatment, and relapse as the reappearance 
of symptoms and signs after completion of antibrucellar 
treatment. Relapses were evaluated only in patients who 
had a follow-up period of at least 6 months post-therapy, 
whereas therapeutic failures were estimated in all treated 
patients irrespective of the follow-up period.
Patients were hospitalized until clinical improvement was 
achieved. Laboratory and serological controls were con-
ducted on the 15th and 40th day of the treatment. In the 
follow-up period, these controls were done once a month 
during the first three months, and then every two to six 
months until the patient stopped coming for check-ups. 
Controls were conducted earlier if signs and symptoms ag-
gravated or re-appeared after clinical cure. In the case of a 
relapse, the same diagnostic and therapeutic procedures 
were performed as in the initial episode of the disease.
Age, illness duration prior to diagnosis, treatment dura-
tion and follow-up period are presented using median 
and range values. All other parameters are presented as 
frequencies and percentages. Statistical analysis was per-
formed using the SPSS, version 8.0 (SPSS, Inc., Chicago, 
IL, USA).
ReSuLtS
The patients were 1 to 82 years old (median, 34.5). Most 
of them belonged to the age group 15-40 years (n = 252 
patients, 46%), followed by the age group 41-60 years 
(n = 132, 24%). The number of patients younger than 14 
(n = 86, 16%) was nearly the same as the number of those 
older than 60 years (n = 80, 15%). The male/female ratio 
was 395/155 (72/28%). Four female patients were preg-
nant at the time when the diagnosis was established.
An occupational exposure was reported by 333 (61%) pa-
tients. The ingestion of potentially contaminated food was 
mentioned by 155 (28%) patients. In 62 (11%) patients, 
the mode of transmission remained obscure. Three hun-
dred and ten patients (56%) belonging to 103 families, 
had a confirmed family history of brucellosis in at least 
one of their members. Patients presented at the hospital 
most frequently during the spring (n = 216, 39%) and sum-
mer (n = 183, 33%). The nadir of brucellosis was in winter 
(n = 95, 17%) and fall (n = 56, 10%).
The median illness duration prior to diagnosis was 30 
days (range, 3 to 360). More than 60% of patients were 
diagnosed within 30 days, and 80% within 60 days after 
the onset of symptomatic disease (Figure 1). The clinical 
characteristics, laboratory findings, and initial serologi-
cal titers at the time of admission are shown in Table 1 to 
Table 3, respectively. Osteoarticular involvement was the 
most frequent focal complication, found in 299 (54%) pa-
tients. Patients presented with peripheral arthritis (n = 187, 
34%), sacroiliitis (n = 68, 12%), spondylitis (n = 78, 14%), and 
miscellaneous osteoarticular forms (n = 11, 2%). The geni-
tourinary, respiratory, hematological, nervous, hepatobili-
ary, cardiovascular, and other organ systems were affected, 
respectively, in 36 (6.5%), 34 (6.2%), 32 (5.8%), 19 (3.4%), 15 
(2.7%), 10 (1.8%), and 6 (1.1%) patients.
Eighty-six patients (16%) were treated with a combination 
of two drugs; in the remaining 464 (84%) patients three 
drugs were used. Three hundred and nineteen (58%) pa-
tients were treated with a combination of doxycycline, ri-
fampin, and trimethoprim/sulfamethoxazole; 62 (11%) with 
a combination of doxycycline, rifampin, and gentamicin; 
53 (10%) with a combination of doxycycline and rifampin; 
and 31 (6%) with a combination of rifampin and TMP/SMZ. 
In the remaining 85 (15%) patients, other therapeutic regi-
mens were used. Treatment duration was median 45 days 
(range 45-360). In 102 (18%) patients, treatment duration 
was prolonged for at least 90 days. Corticosteroids were 
used in 15, 12, 11, and 4 patients presenting with menin-
go/myelo/radiculo/neuritis, thrombocytopenia/ pancyto-
Figure 1.
Illness duration before diagnosis in 550 patients with brucellosis diag-
nosed and treated during 1998-2007 at the university Clinic for Infec-
tious Diseases and Febrile Conditions in Skopje.
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penia, orchitis/orchoepididymitis, and vasculitis as a con-
sequence of brucellosis, respectively.
The outcome of the pregnancy in the 4 expecting patients 
was spontaneous deliveries in 3 (1 premature, 2 in-term) and 
1 abortion. One patient with brucellar endocarditis under-
went a cardiac surgery and valve replacement. Two patients 
died within the treatment period: the first fatal outcome was 
a result of a myocardial infarction, and the second of renal 
and respiratory complications due to brucellosis. Therapeu-
tic failures occurred in 37 (6.7%) patients. The median follow-
up of our patients was 10 months (range, 0-84) post-therapy. 
A follow-up period of ≥6 months was recorded in 453 (82%) 
cases, 60 (13%) of which relapsed.
DISCuSSIon
Most of the patients with brucellosis in our study were 
men and belonged to the age group 15-40 years. Age dis-
tribution of the study population is important because it 
may influence the clinical expression of brucellosis, includ-
ing the frequency and type of signs, symptoms, complica-
tions (18,28-30).
The age distribution of the patients in our study did not dif-
fer significantly from that of patients in other studies (19,28). 
The frequency of brucellosis among children (≤14 years) 
in our study was similar to that reported in other studies 
(20,28); in fact, in several other studies, nearly one of every 
taBLe 1. Frequency of clinical characteristics in patients with brucellosis, as reported in our and other studies
















Aygen et al (14)  80  90  84  82  39  21  14
Yinnon (18)  96  33  ND*  35  ND  55  69
Memish et al (19)  91  ND  19  66  84   6   7
Andriopoulos et al (20) 100  97  96  87  ND  25  51
Shehabi et al (21) 100  ND  88  60  ND  54  61
Demiroglu et al (22)  80  86  78  87  ND  ND  ND
Tasbakan et al (23)  94  96  92  82  97  38  60
Pourbagher et al (24)  55  76  53  85  ND   6   8
Trujillo et al (25) 100  77  96  81  ND  10  12
Buchanan et al (26)  ND  95  93  17  95  ND  ND
Kokoglu et al (27)  78  ND  72  78  41  27  36
Present study, No. (%) 419 (76) 377 (68) 394 (72) 438 (80) 357 (65) 273 (50) 159 (29)
*abbreviation: nD – not determined.
taBLe 2. Frequency of hematological and biochemical features in patients with brucellosis, as reported in our and other studies*































1  ND  ND  24  2 ND 40  5 ND 2
13  ND  ND  31 27 ND ND 15 31 2
14  59  ND  ND  8 6 68 ND 55 ND
18  ND  ND  40 31 3 55  3 51 ND
24  49  23  10 ND ND ND ND 30 ND
28  ND  74  39 14 8 32 ND 70 ND
29  42  48  18  6 4 ND ND ND ND
30  77  ND  40 19 9 41  8  7 3.5
Present study, 
No. (%)
337 (63)† 389 (79)‡ 180 (33) 50 (9.1) 45 (8.2) 132 (24) 58 (12)§ 148 (27) 3 (0.6)§
*abbreviations: nD – not determined.
†Measured in 535 patients.
‡Measured in 490 patients.
§Measured in 500 patients.
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four patients fell into this age group (3,18,19,21,31). In an 
Iranian study, 56% of the examined patients were younger 
than 14 years (32). The frequency of patients older than 60 
years varied from 2% (33-35) to 32% (36). A high frequency 
in older age groups was also found in a study conducted 
in northwestern Greece (37).
Consistent with our results, the majority of studies indicate 
that men are infected more often, ie, in 55% (15,19,38-42) or 
even 96% of the cases (34). Nevertheless, sex distribution of 
patients with brucellosis varies widely: several studies have 
indicated either equal distribution (21,28,43,44) or, in some 
cases, predominance of female patients (14,22,29,45).
Gotuzzo et al detected a more severe course of the dis-
ease in women, especially those with brucellar arthritis 
(46). However, the complication rate seems to be higher in 
men (15). Headaches and lethargy are more frequently ob-
served in women and splenomegaly in males (3).
Age and sex distribution found in this study is a result of 
regional habits, mostly due to husbandry practices that 
make working-age men most vulnerable to brucellosis.
Nevertheless, brucellosis can be found in women, as well 
as marginal age groups due to consumption of food prod-
ucts of animal origin (eg, young cheese from sheep or 
goats) that are not adequately thermally processed.
The epidemiology of brucellosis often remains obscure 
and is not well defined. In patients with professional ex-
posure, besides the skin and conjunctival contact, the in-
fection can be acquired both by airborne transmission 
and by ingestion of contaminated animal products (45). 
Hence, risk assessment is often subjective. Some authors 
think that occupational exposure risk is the most impor-
tant (28,41), others favor the transmission by animal food 
(described in 63%-92% of the patients) (20,23,24,33,38,45), 
whereas in several studies the mode of transmission re-
mains unknown for up to 57% of the patients (15,47). It is 
of particular importance to understand the mode of bru-
cellosis transmission since this knowledge helps to apply 
appropriate countermeasures.
Our study confirmed that screening the family members 
of a brucellosis patient is an important issue. Family his-
tory of brucellosis was reported in 9% to 51% of patients 
(15,24,46,48). Family screening leads to early diagnosis of 
the disease, which may prevent complications (49,50).
Brucellosis duration prior to diagnosis is an important pa-
rameter in assessing the clinical course and outcome. It 
has been recognized that brucellosis duration without ad-
equate treatment is directly correlated with the compli-
cation rate and unfavorable outcome (41). A long period 
of symptomatic disease before therapeutic intervention 
was significantly more frequent in patients with brucellar 
spondylitis than in patients without spondylitis (12,48). The 
percentage of relapses among patients suffering from the 
disease for more than a month before therapy was high-
er than that among patients suffering from the disease for 
less than a month (29). Contradictory to these findings, 
other studies demonstrated that treatment beginning less 
than 10 days after disease onset led to higher relapse rates 
(51,52). In endemic countries, brucellosis may be diag-
nosed earlier because physicians are familiar with the clini-
cal signs and symptoms and take it more often into con-
sideration as a differential diagnosis. However, this is not 
always the case. In some series, 16% of patients were di-
agnosed with a delay of more than three months after the 
onset of symptoms (41,47). The diagnostic delay could be 
a result of either misdiagnosis or postponed visit to a medi-
cal professional (8,53).
Clinical and laboratory features are often not pathogno-
monic for human brucellosis and differ widely (Table 1 and 
Table 2). In addition, the number of patients suffering from 
focal involvement ranges from 6% to 92% (20,21,42,54) and 
is usually about 30% (14,15,38,41,55). In our study, two-
thirds of the enrolled patients had focal manifestations 
and osteoarticular forms predominated, similar to other 
reports (1,15,20,28,44). The wide variation in the frequen-
cies of clinical manifestations may reflect the character-
istics of the examined population, the nature of the 
taBLe 3. number (and percent) of patients showing the 
indicated anti-Brucella antibody titers as measured using the 
serum tube agglutination (Sta) test, Coombs test, or Brucel-
lacapt at the time of admission to hospital*
titer Sta† Brucella Coombs† Brucellacapt‡§
≤1/80  24 (7)   0   0
1/160  34 (10)  28 (8)   4 (2)
1/320  51 (15)  43 (12)   8 (4)
1/640  82 (24)  67 (20)  20 (10)
1/1280 153 (44) 206 (60)  20 (10)
1/2560  ND  ND  29 (14)
1/5120  ND  ND 125 (61)
*abbreviation: nD – not determined.
†Performed in 344 patients.
‡Performed in 206 patients.
§the numbers do not add up to 100% because of rounding.
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causative agent, geographic variations of the disease, the 
stage of disease, the diversity of case definition criteria, the 
diagnostic procedures, and the type of study (retrospec-
tive or prospective) (12).
The serum agglutination test is an important diagnostic 
tool, bearing in mind that bacterial isolation methods are 
time-consuming, show lack sensitivity, and pose risk to 
laboratory personnel (56). The combination of the serum 
agglutination test and Coombs tests in diagnosing the dis-
ease may help to overcome the problem of false-negative 
results (1,57). Recently, the Brucellacapt test has started to 
replace other serological tests (58,59). Serological evalua-
tion of our results at the time of admission to hospital gen-
erally showed high anti-Brucella antibody titers, especially 
in the Coombs test and the Brucellacapt. In the case of in-
conclusive serological results but a high clinical suspicion 
of brucellosis, the patients were retested after 2-4 weeks to 
assess possible seroconversion (19).
The primary goal of brucellosis therapy is to control the 
illness and prevent complications, relapses, and sequels 
(60). The currently recommended treatment regimens are 
based upon the recommendations of the World Health Or-
ganization in 1986 (61), updated by experts in the field at 
the Conference for Treatment of Human Brucellosis held in 
Ioannina, Greece, in 2006 (62). Nevertheless, a great diver-
sity of therapeutic protocols exists. The selection of antimi-
crobial agents depends on the clinical presentation, age 
of the patient, pregnancy, drug side effects, and co-mor-
bidity; in addition, in regions with scarce resources, thera-
peutic decisions are also determined by treatment costs 
and drug availability. The triple antimicrobial combination 
is rarely implemented and its use is traditionally restricted 
to patients with neurobrucellosis, endocarditis, or abscess-
es (3,23,63,64). Nevertheless, the highest cure rate can be 
achieved with a triple therapy (3) and adding a third drug 
to the standard regimen seems to be beneficial (63). In two 
reports, children treated with three drugs had a better out-
come than those treated with two drugs (65,66). Almost 
84% of the patients in the present study were treated with 
a combination of three antimicrobial agents, based on our 
previous experience that three-drug therapy was better 
than two-drug therapy (unpublished data).
In the first epidemiological study on human brucellosis in 
Malta during the period 1901-1907, when understanding 
of the disease was very limited and treatment was inad-
equate, Eyre reported that the mortality rate among 
the civilian population was approximately 10%, and 
2.3% among soldiers and marines (7,67). In the recent de-
cades with the use of appropriate antimicrobial treatment, 
the mortality rate has been lower than 1% (4,14,29,41,68). 
However, there are exceptions, in non-endemic countries 
as a result of the decreasing knowledge about the disease 
and in endemic regions of the developing world due to 
lack of medical care. For instance, in Germany, mortality 
rates increased from 0.4% (1978-1981) to a maximum of 
6.5% (1998-2001) (69). In Nigeria, a mortality rate of 5.4% 
was reported (70). Of course, mortality rates might be bi-
ased by the selection of patients with specific clinical 
manifestations; for example, the rate was 2.1% in a series 
of patients with vertebral osteomyelitis in Spain (71). Bru-
cella endocarditis is the main cause of death attributable 
to this disease (72-74), but many other causes have been 
described, eg, endotoxic shock with disseminated intravas-
cular coagulation (75), rupture of a mycotic aneurysm (76), 
aortitis with mesenteric thrombosis (41), myocarditis (77), 
dissemination with multifocal liver and lung nodules (78), 
thrombocytopenia (79), and neurobrucellosis (14,29,41). 
We had only one mortality case as a direct consequence 
of brucellosis. The main reason for fatal outcome was de-
velopment of renal and respiratory failure, which can be 
added to the above list of rare causes of fatal outcome in 
patients with brucellosis.
Therapeutic failures and relapses are inevitable character-
istics of the disease. Unfavorable outcomes usually have to 
be ascribed to the inability to eradicate the bacteria from 
their intracellular niche. In adequately treated patients, re-
lapses occur in 0 to 16% of the cases (14,31,33,38,41,45,80-
82). The frequency of relapses found in our patients is sim-
ilar to those mentioned in other reports (27,35,83-85). In 
our study, only patients with a follow-up period of at least 
6 months post-therapy were included when assessing the 
relapse rate. If we included the patients with a follow-up 
period shorter than 6 months, eg, those who had never 
showed up for a check-up or who had come to only one, 
we would have underestimated the relapse rate, given 
that relapses most frequently appear in brucellosis during 
the first 6 months after the end of treatment (52,86). Pos-
sible reasons for relapse are inadequate choice of antibi-
otics, short treatment duration, and a lack of compliance. 
However, the relapse rate may be biased by the inability to 
distinguish re-infections from relapses and short follow-up 
periods (12). Therapeutic failures, which occurred in 6.7% 
of patients in our study, are mostly associated with brucel-
lar spondylitis (12,41,48,87). According to literature data, 
the frequency of therapeutic failures varies from 0 to 15% 
(17,22,23,33,38,41,42,55,80).
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Our study has two main limitations. First, we did not use 
Brucellae isolation, which is important for disease diagno-
sis, determination of Brucella species, detection of relaps-
es, and follow-up of antimicrobial sensitivity. Second, this 
study was retrospective and data were sometimes missing 
about biochemical tests or other diagnostic findings such 
as magnetic resonance imaging, which has since then be-
come the preferred procedure for patients with spondyli-
tis, but which was performed in our study in only 29 of 78 
(37%) patients with this condition. In addition, since the 
study was retrospective, the study group included many 
different therapy combinations and longer follow-up for 
some of the patients was not possible.
In summary, brucellosis is still a serious public health prob-
lem in the Republic of Macedonia. For early diagnosis, 
considering family history of the disease is important and 
special emphasis should be placed on asking about oc-
cupational exposure and family members suffering from 
brucellosis. Keeping in mind that clinical and laboratory 
characteristics of the disease are heterogeneous and non-
specific, brucellosis has to be considered in the differential 
diagnoses of patients with complex organ involvement re-
ferred to hospitals in endemic regions and in travelers re-
turning from endemic regions. The high relapse and thera-
peutic failure rates, despite the use of an adequate therapy, 
show the seriousness of this zoonosis and the absolute 
need to control it in the animal reservoir.
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